Heiskanen Jari, Hartikainen Sirpa, Roine Risto P, Tolppanen Anna-Maija
Research Centre for Comparative Effectiveness and Patient Safety (RECEPS), University of Eastern Finland, Kuopio, Finland.
School of Pharmacy, University of Eastern Finland, Kuopio, Finland.
J Alzheimers Dis. 2015;48(1):241-9. doi: 10.3233/JAD-150259.
Persons with Alzheimer's disease (AD) have been suggested to receive suboptimal treatment. We studied the 30-day mortality after ischemic stroke, hemorrhagic stroke, or myocardial infarction in individuals with or without AD.
An exposure matched cohort of all Finnish community-dwellers diagnosed with clinically verified AD in 2005-2012 (n = 73,005) and 1-4 matched comparison persons/AD-affected person (n = 215,449). Data on 30-day mortality after ischemic stroke (n = 16,419; deaths: n = 2,748), hemorrhagic stroke (n = 3,570; deaths: n = 1,224), and myocardial infarction (n = 15,304; deaths: n = 3,804) were obtained from the National Hospital Discharge register. The main analyses were restricted to first-ever events.
Persons with AD had slightly higher 30-day mortality after ischemic stroke (adjusted HR 1.36, 95% Confidence interval (CI) 1.24,1.49), hemorrhagic stroke (adjusted HR 1.11, 95% CI 0.98,1.25), or myocardial infarction (adjusted HR, 1.40, 9% CI 1.30,1.51). The associations were not affected by age, gender, or co-morbidities and remained similar when patients with previous ischemic strokes or infarctions were included. The absolute risk increase in 30-day mortality after ischemic or hemorrhagic stroke and myocardial infarction were 4.9% (95% CI 3.3,6.5), 3.3% (95% CI - 1.6,8.2), and 7.5% (95% CI 5.0,10.0), respectively.
Although the 30-day mortality was somewhat higher in the AD cohort, the absolute differences were small indicating that acute treatment was not notably inferior in AD patients. The slightly higher mortality was not explained by co-morbidities but may reflect the higher mortality of AD persons in general, or treatment practice of patients with severe cognitive impairment.
有研究表明,阿尔茨海默病(AD)患者接受的治疗不够理想。我们研究了患有或未患有AD的个体在发生缺血性卒中、出血性卒中和心肌梗死后30天的死亡率。
选取2005 - 2012年在芬兰社区居住且经临床确诊患有AD的所有患者(n = 73,005)作为暴露匹配队列,为每例AD患者匹配1 - 4名对照者(n = 215,449)。缺血性卒中(n = 16,419;死亡人数:n = 2,748)、出血性卒中(n = 3,570;死亡人数:n = 1,224)和心肌梗死(n = 15,304;死亡人数:n = 3,804)后30天死亡率的数据来自国家医院出院登记册。主要分析仅限于首次发生的事件。
患有AD的个体在缺血性卒中(校正风险比1.36,95%置信区间(CI)1.24,1.49)、出血性卒中(校正风险比1.11,95% CI 0.98,1.25)或心肌梗死后30天死亡率略高(校正风险比1.40,9% CI 1.30,1.51)。这些关联不受年龄、性别或合并症的影响,纳入既往有缺血性卒中和梗死的患者后结果仍相似。缺血性或出血性卒中和心肌梗死后30天死亡率的绝对风险增加分别为4.9%(95% CI 3.3,6.5)、3.3%(95% CI - 1.6,8.2)和7.5%(95% CI 5.0,10.0)。
虽然AD队列中的30天死亡率略高,但绝对差异较小,表明AD患者的急性治疗并非明显较差。死亡率略高并非由合并症所致,可能反映了AD患者总体死亡率较高,或严重认知障碍患者的治疗情况。